- GreenLight Biosciences ( NASDAQ: GRNA ) and partner Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies' mRNA COVID-19 vaccine.
- After the announcement of the partnership, technology transfer and scale-up from the lab bench to Samsung's commercial facility was completed in seven months.
- The companies said commercial-scale run has demonstrated production—in a single facility—of both Drug Substance and LNP formulation, allowing the production of bulk Drug Product.
- ( GRNA ) is up 3.6% .
For further details see:
GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine